__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Metastatic treatment

 

Patient guide to stage III melanoma with Taflinar + Mekinist

This guide and the Tafinlar and Mekinist Patient Diary are designed to help your patients work with their healthcare team throughout their treatment for stage III BRAF positive melanoma.

It includes valuable information such as:

  • What is melanoma?
  • What are Tafinlar and Mekinist?
  • How to take Tafinlar and Mekinist
  • How to store Tafinlar and Mekinist
  • Contraceptive and fertility information
  • Possible drug interactions
  • What to expect
  • Possible side effects and
  • A treatment diary
Rate this content: 
No votes yet
IE212359 | June 2024
×

Ask Speakers

×

Medical Information Request

Reporting of side effects
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported to HPRA Pharmacovigilance, website www.hpra.ie. Adverse events can also be reported to Novartis preferably at www.novartis.com/report, by emailing [email protected] or by calling (01) 2080 612.